IO Biotech: Cylembio Targeting Advanced Melanoma Continues Towards Q3 PFS Data Release

Stock Information for IO Biotech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About IO Biotech Inc.

IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications
IO Biotech Announces Participation in Upcoming December Investor Conferences
IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights
IO Biotech Announces Participation in Upcoming Investor Conferences
IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
IO Biotech Provides Update Following Pre-BLA Meeting with FDA

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.